XL888 is an oral formulation HSP90 inhibitor.
Link here for information at the manufacturer's website.
Link here for a pdf of a poster about lab rat research with this drug presented at the 2008 EORTC meeting.
You can use the magnification control within the Adobe reader to enlarge the poster for easy reading.
XL888 has entered a phase I human trial:
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
NCT00796484, Phase I, recruiting